#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.

POST Online Media Lite Edition


New executive leadership and CEO at BiPar Sciences

Staff writer |
Bridgewater, N.J., USA - December 11, 2009, Bridgewater, N.J., USA - Sanofi-aventis and its wholly-owned subsidiary BiPar Sciences announced changes to the executive management team at BiPar Sciences.

BiPar chief executive officer and president Hoyoung Huh, M.D., Ph.D. will take on a broader role in the sanofi-aventis organization as Chairman of the Board of Directors of BiPar, as well as chair of the newly formed BiPar Innovation Board. As part of this new role, Dr. Huh will serve as advisor to sanofi-aventis Chief Executive Officer Christopher A. Viehbacher and to Executive Vice President Research and Development Marc Cluzel, as well as to the Executive Committee, in the areas of innovation, R&D transformation, and entrepreneurship.

Sanofi-aventis has appointed Atul Dhir, M.D., Ph.D. as Chief Executive Officer of BiPar Sciences effective December 1, 2009. Dr. Dhir's mission is to continue developing the innovative BiPar portfolio, including the ongoing clinical program of BSI-201 - which, of an emerging class of investigational compounds (PARP inhibitors), is currently the furthest along in the Phase 3 clinical development in the metastatic triple negative breast cancer setting.


What to read next

Geron Corporation adds two new directors
AntriaBio appoints Barry Sherman to board
OncoMed Pharmaceuticals: Sunil Patel senior vice president